These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 38295343)

  • 1. Tubular phosphate transport: a comparison between different methods of urine sample collection in FGF23-dependent hypophosphatemic syndromes.
    Arcidiacono GP; Camozzi V; Zaninotto M; Tripepi G; Fusaro M; Torres MO; Zanchetta F; Cannito M; Cecchinato A; Diogo M; Peleg Falb M; Plebani M; Simioni P; Sella S; Giannini S
    Clin Chem Lab Med; 2024 May; 62(6):1126-1132. PubMed ID: 38295343
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasma intact fibroblast growth factor 23 level is a useful tool for diagnostic approach of renal hypophosphatemia.
    Giralt M; Chocron S; Ferrer R; Ariceta G
    Pediatr Nephrol; 2021 Apr; 36(4):1025-1028. PubMed ID: 33492457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical value of renal phosphorus threshold in the diagnosis and treatment X-linked hypophosphatemic rickets in children].
    Tao JQ; Chen Y
    Zhongguo Dang Dai Er Ke Za Zhi; 2024 Sept 15; 26(9):926-932. PubMed ID: 39267507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of burosumab in improving phosphate metabolism, bone health, and quality of life in adolescents with X-linked hypophosphatemic rickets.
    Baroncelli GI; Grandone A; Aversa A; Sessa MR; Pelosini C; Michelucci A; Toschi B; Manca M; Isola A; Comberiati P
    Eur J Med Genet; 2024 Aug; 70():104958. PubMed ID: 38950880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble klotho and autosomal dominant polycystic kidney disease.
    Pavik I; Jaeger P; Ebner L; Poster D; Krauer F; Kistler AD; Rentsch K; Andreisek G; Wagner CA; Devuyst O; Wüthrich RP; Schmid C; Serra AL
    Clin J Am Soc Nephrol; 2012 Feb; 7(2):248-57. PubMed ID: 22193235
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement in the mobility of a patient with fibroblast growth factor 23-related hypophosphatemic osteomalacia and decompensated liver cirrhosis in response to burosumab: a case report.
    Toi N; Imanishi Y; Nagata Y; Kurajoh M; Morioka T; Shoji T; Shinto Y; Emoto M
    Endocr J; 2023 Apr; 70(4):419-426. PubMed ID: 36575021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intact Fibroblast Growth Factor 23 Concentrations in Hypophosphatemic Disorders.
    Ramos P; Larson B; Ashrafzadeh-Kian S; Ito N; Kato H; Bornhorst JA; Algeciras-Schimnich A
    Endocr Pract; 2023 Mar; 29(3):193-198. PubMed ID: 36627024
    [TBL] [Abstract][Full Text] [Related]  

  • 8. X-Linked Hypophosphatemia and FGF23-Related Hypophosphatemic Diseases: Prospect for New Treatment.
    Kinoshita Y; Fukumoto S
    Endocr Rev; 2018 Jun; 39(3):274-291. PubMed ID: 29381780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia.
    Carpenter TO; Imel EA; Ruppe MD; Weber TJ; Klausner MA; Wooddell MM; Kawakami T; Ito T; Zhang X; Humphrey J; Insogna KL; Peacock M
    J Clin Invest; 2014 Apr; 124(4):1587-97. PubMed ID: 24569459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reflections on TRP and TP/GFR in the definition of renal phosphate loss: conceptual review.
    García-Nieto VM; González-Rodríguez JD; Cabrera-Sevilla JE; Martín-Fernández de Basoa MC; Luis-Yanes MI
    Pediatr Nephrol; 2023 Nov; 38(11):3845-3848. PubMed ID: 37052691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FGF23-related hypophosphatemic rickets/osteomalacia: diagnosis and new treatment.
    Fukumoto S
    J Mol Endocrinol; 2021 Feb; 66(2):R57-R65. PubMed ID: 33295878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prolonged Correction of Serum Phosphorus in Adults With X-Linked Hypophosphatemia Using Monthly Doses of KRN23.
    Imel EA; Zhang X; Ruppe MD; Weber TJ; Klausner MA; Ito T; Vergeire M; Humphrey JS; Glorieux FH; Portale AA; Insogna K; Peacock M; Carpenter TO
    J Clin Endocrinol Metab; 2015 Jul; 100(7):2565-73. PubMed ID: 25919461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. X-Linked Hypophosphatemia: Uniquely Mild Disease Associated With PHEX 3'-UTR Mutation c.*231A>G (A Retrospective Case-Control Study).
    Smith PS; Gottesman GS; Zhang F; Cook F; Ramirez B; Wenkert D; Wollberg V; Huskey M; Mumm S; Whyte MP
    J Bone Miner Res; 2020 May; 35(5):920-931. PubMed ID: 31910300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The concurrence of hypoparathyroidism provides new insights to the pathophysiology of X-linked hypophosphatemic rickets.
    Lyles KW; Burkes EJ; McNamara CR; Harrelson JM; Pickett JP; Drezner MK
    J Clin Endocrinol Metab; 1985 Apr; 60(4):711-7. PubMed ID: 4038714
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Burosumab Treatment on Mineral Metabolism in Children and Adolescents With X-linked Hypophosphatemia.
    Ewert A; Rehberg M; Schlingmann KP; Hiort O; John-Kroegel U; Metzing O; Wühl E; Schaefer F; Kemper MJ; Derichs U; Richter-Unruh A; Patzer L; Albers N; Dunstheimer D; Haberland H; Heger S; Schröder C; Jorch N; Schmid E; Staude H; Weitz M; Freiberg C; Leifheit-Nestler M; Zivicnjak M; Schnabel D; Haffner D
    J Clin Endocrinol Metab; 2023 Sep; 108(10):e998-e1006. PubMed ID: 37097907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined treatment by burosumab and a calcimimetic can ameliorate hypophosphatemia due to excessive actions of FGF23 and PTH in adult XLH with tertiary hyperparathyroidism: A case report.
    Takashi Y; Toyokawa K; Oda N; Muta Y; Yokomizo H; Fukumoto S; Kawanami D
    Front Endocrinol (Lausanne); 2022; 13():1004624. PubMed ID: 36531500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement.
    Endo I; Fukumoto S; Ozono K; Namba N; Tanaka H; Inoue D; Minagawa M; Sugimoto T; Yamauchi M; Michigami T; Matsumoto T
    Bone; 2008 Jun; 42(6):1235-9. PubMed ID: 18396126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Congenital hypophosphataemia in adults: determinants of bone turnover markers and amelioration of renal phosphate wasting following total parathyroidectomy.
    McKenna MJ; Martin-Grace J; Crowley R; Twomey PJ; Kilbane MT
    J Bone Miner Metab; 2019 Jul; 37(4):685-693. PubMed ID: 30238432
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in fibroblast growth factor 23-related hypophosphatemic disorders.
    Takashi Y; Kawanami D; Fukumoto S
    Curr Opin Endocrinol Diabetes Obes; 2024 Aug; 31(4):170-175. PubMed ID: 38687287
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Renal tubular reabsorption of phosphate (TmP/GFR): indications and interpretation.
    Payne RB
    Ann Clin Biochem; 1998 Mar; 35 ( Pt 2)():201-6. PubMed ID: 9547891
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.